Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference, 4th edition, 372 pages

+ the daily Top 10


  Prostate Cancer

  Free Subscription


Articles published in Br J Radiol

Retrieve available abstracts of 71 articles:
HTML format



Single Articles


    July 2020
  1. TAYLOR T, Richmond N
    A UK wide study of current prostate planning practice.
    Br J Radiol. 2020;93:20200142.
    PubMed     Abstract available


    June 2020
  2. ASHTON J, Bristow R
    Bad neighbours: hypoxia and genomic instability in prostate cancer.
    Br J Radiol. 2020 Jun 18:20200087. doi: 10.1259/bjr.20200087.
    PubMed     Abstract available


  3. ZAWAIDEH JP, Sala E, Pantelidou M, Shaida N, et al
    Comparison of likert and PI-RADS version 2 MRI scoring systems for the detection of clinically significant prostate cancer.
    Br J Radiol. 2020 Jun 1:20200298. doi: 10.1259/bjr.20200298.
    PubMed     Abstract available


    April 2020
  4. DEVLIN L, Dodds D, Sadozye A, McLoone P, et al
    Dosimetric impact of organ at risk daily variation during prostate stereotactic ablative radiotherapy.
    Br J Radiol. 2020;93:20190789.
    PubMed     Abstract available


    March 2020
  5. EMARA DM, Naguib NN, Yehia M, El Shafei MM, et al
    Ultrasound elastography in characterization of prostatic lesions: correlation with histopathological findings.
    Br J Radiol. 2020 Mar 6:20200035. doi: 10.1259/bjr.20200035.
    PubMed     Abstract available


    February 2020
  6. ADRIAN G, Konradsson E, Lempart M, Back S, et al
    The FLASH effect depends on oxygen concentration.
    Br J Radiol. 2020;93:20190702.
    PubMed     Abstract available


    January 2020
  7. DEANTONI CL, Fodor A, Cozzarini C, Fiorino C, et al
    Prostate cancer with low burden skeletal disease at diagnosis: outcome of concomitant radiotherapy on primary tumor and metastases.
    Br J Radiol. 2020 Jan 23:20190353. doi: 10.1259/bjr.20190353.
    PubMed     Abstract available


  8. SUSHENTSEV N, Caglic I, Sala E, Shaida N, et al
    The effect of capped biparametric magnetic resonance imaging slots on weekly prostate cancer imaging workload.
    Br J Radiol. 2020 Jan 23:20190929. doi: 10.1259/bjr.20190929.
    PubMed     Abstract available


  9. KEENAN L, Ibrahim N, Dunne MT, Finn M, et al
    The effect of anaemia on normal tissue toxicity and survival outcomes in prostate cancer treated with radical radiotherapy and neo-adjuvant androgen deprivation.
    Br J Radiol. 2020 Jan 16:20190577. doi: 10.1259/bjr.20190577.
    PubMed     Abstract available


  10. KIM E, Kim CK, Kim HS, Jang DP, et al
    Histogram analysis from stretched exponential model on diffusion-weighted imaging: evaluation of clinically significant prostate cancer.
    Br J Radiol. 2020 Jan 9:20190757. doi: 10.1259/bjr.20190757.
    PubMed     Abstract available


  11. WANG T, Zhou J, Tian S, Wang Y, et al
    A planning study of focal dose escalations to multiparametric MRI-defined dominant intraprostatic lesions in prostate proton radiation therapy.
    Br J Radiol. 2020 Jan 6:20190845. doi: 10.1259/bjr.20190845.
    PubMed     Abstract available


    December 2019
  12. TSANG YM, Vignarajah D, Mcwilliam A, Tharmalingam H, et al
    A pilot study on dosimetric and radiomics analysis of urethral strictures following HDR brachytherapy as monotherapy for localized prostate cancer.
    Br J Radiol. 2019 Dec 2:20190760. doi: 10.1259/bjr.20190760.
    PubMed     Abstract available


    November 2019
  13. BHATTACHARYYA T, Koto M, Ikawa H, Hayashi K, et al
    First prospective feasibility study of carbon-ion radiotherapy using compact superconducting rotating gantry.
    Br J Radiol. 2019;92:20190370.
    PubMed     Abstract available


    October 2019
  14. SUMAN S, Parghane RV, Joshi A, Prabhash K, et al
    Therapeutic efficacy, Prognostic variables and Clinical Outcome of (177)Lu-PSMA-617 PRLT in Progressive mCRPC following multiple lines of treatment: prognostic implications of high FDG uptake on dual tracer PET-CT vis-a-vis Gleason Score in such cohor
    Br J Radiol. 2019 Oct 10:20190380. doi: 10.1259/bjr.20190380.
    PubMed     Abstract available


  15. ZHANG F, Liu CL, Chen Q, Shao SC, et al
    Accuracy of multiparametric magnetic resonance imaging for detecting extracapsular extension in prostate cancer: a systematic review and meta-analysis.
    Br J Radiol. 2019 Oct 9:20190480. doi: 10.1259/bjr.20190480.
    PubMed     Abstract available


  16. MAHDAVI SR, Tavakol A, Sanei M, Molana SH, et al
    Use of artificial neural network for pretreatment verification of intensity modulation radiation therapy fields.
    Br J Radiol. 2019;92:20190355.
    PubMed     Abstract available


    September 2019
  17. SCHICK U, Lucia F, Dissaux G, Visvikis D, et al
    MRI derived radiomics: Methodology and clinical applications in the field of pelvic oncology.
    Br J Radiol. 2019 Sep 20:20190105. doi: 10.1259/bjr.20190105.
    PubMed     Abstract available


    July 2019
  18. SUN Y, Williams S, Byrne D, Keam S, et al
    Association analysis between quantitative MRI features and hypoxia-related genetic profiles in prostate cancer: a pilot study.
    Br J Radiol. 2019 Jul 30:20190373. doi: 10.1259/bjr.20190373.
    PubMed     Abstract available


  19. KIM SJ, Lee SW
    Diagnostic accuracy of (F)18 flucholine PET/CT for preoperative lymph node staging in newly diagnosed prostate cancer patients; a systematic review and meta-analysis.
    Br J Radiol. 2019 Jul 5:20190193. doi: 10.1259/bjr.20190193.
    PubMed     Abstract available


  20. KISHAN AU, Tyran M, Weng J, Upadhyaya S, et al
    Stereotactic body radiotherapy to the prostate and pelvic lymph nodes: A detailed dosimetric analysis of a phase II prospective trial.
    Br J Radiol. 2019;92:20181001.
    PubMed     Abstract available


    June 2019
  21. ACAR E, Leblebici A, Ellidokuz BE, Basbinar Y, et al
    Machine learning for differentiating metastatic and completely responded sclerotic bone lesion in prostate cancer: A retrospective radiomics study.
    Br J Radiol. 2019 Jun 20:20190286. doi: 10.1259/bjr.20190286.
    PubMed     Abstract available


  22. SUREKA B, Elhence P, Khera PS, Choudhary GR, et al
    Quantitative contrast-enhanced perfusion kinetics in multiparametric MRI in differentiating prostate cancer from chronic prostatitis: results from a pilot study.
    Br J Radiol. 2019 Jun 11:20190181. doi: 10.1259/bjr.20190181.
    PubMed     Abstract available


  23. DE LEON J, Jameson MG, Rivest-Henault D, Keats S, et al
    Reduced motion and improved rectal dosimetry through endorectal immobilization for prostate stereotactic body radiotherapy.
    Br J Radiol. 2019;92:20190056.
    PubMed     Abstract available


    April 2019
  24. TAMPONI M, Gabriele D, Maggio A, Stasi M, et al
    Prostate cancer dose-response, fractionation sensitivity and repopulation parameters evaluation from 25 international radiotherapy outcome data sets.
    Br J Radiol. 2019 Apr 24:20180823. doi: 10.1259/bjr.20180823.
    PubMed     Abstract available


  25. LEE SM, Wolfe K, Acher P, Liyanage SH, et al
    Multiparametric MRI appearances of primary granulomatous prostatitis.
    Br J Radiol. 2019 Apr 9:20180075. doi: 10.1259/bjr.20180075.
    PubMed     Abstract available


    March 2019
  26. WANG T, Press RH, Giles M, Jani AB, et al
    Multiparametric MRI-guided dose boost to dominant intraprostatic lesions in CT-based High-dose-rate prostate brachytherapy.
    Br J Radiol. 2019 Mar 26:20190089. doi: 10.1259/bjr.20190089.
    PubMed     Abstract available


  27. KING AJ, Dudderidge T, Darekar A, Schimitz K, et al
    Establishing magnetic resonance imaging guided prostate intervention at a UK Centre.
    Br J Radiol. 2019 Mar 26:20180918. doi: 10.1259/bjr.20180918.
    PubMed     Abstract available


  28. JI Y, Litao R, Ren W, Dun G, et al
    Stiffness of prostate gland measured by transrectal Real-Time shear wave elastography for detection of prostate cancer: A feasibility study.
    Br J Radiol. 2019 Mar 15:20180970. doi: 10.1259/bjr.20180970.
    PubMed     Abstract available


  29. FRANZESE C, D'agostino G, Di Brina L, Navarria P, et al
    Linac-based stereotactic body radiation therapy vs moderate hypofractionated radiotherapy in prostate cancer: propensity-score based comparison of outcome and toxicity.
    Br J Radiol. 2019 Mar 13:20190021. doi: 10.1259/bjr.20190021.
    PubMed     Abstract available


  30. PIERRE DE M, Roberto Luigi C, Julien G, Thibault T, et al
    Percutaneous MR-guided whole-gland prostate cancer cryoablation: safety considerations and oncologic results in 30 consecutive patients.
    Br J Radiol. 2019 Mar 8. doi: 10.1259/bjr.20180965.
    PubMed     Abstract available


    February 2019
  31. WANG H, Cooper BT, Schiff P, Sanfilippo NJ, et al
    Dosimetric assessment of tumor control probability in intensity and volumetric modulated radiotherapy plans.
    Br J Radiol. 2019;92:20180471.
    PubMed     Abstract available


    January 2019
  32. PATHMANATHAN AU, McNair HA, Schmidt MA, Brand DH, et al
    Comparison of prostate delineation on multimodality imaging for MR-guided radiotherapy.
    Br J Radiol. 2019 Jan 24:20180948. doi: 10.1259/bjr.20180948.
    PubMed     Abstract available


  33. COHEN J, Anvari A, Samanta S, Poirier Y, et al
    Mild hyperthermia as a localized radiosensitizer for deep-seated tumors: Investigation in an orthotopic prostate cancer model in mice.
    Br J Radiol. 2019 Jan 23:20180759. doi: 10.1259/bjr.20180759.
    PubMed     Abstract available


    December 2018
  34. NANDURKAR R, van Leeuwen P, Stricker P, Woo H, et al
    (68)Ga-HBEDD PSMA-11 PET/CT staging prior to radical prostatectomy in prostate cancer patients: Diagnostic and predictive value for the biochemical response to surgery.
    Br J Radiol. 2018 Dec 19:20180667. doi: 10.1259/bjr.20180667.
    PubMed     Abstract available


    November 2018
  35. GIACOMETTI V, King RB, Agnew CE, Irvine DM, et al
    An Evaluation of Techniques for Dose Calculation on Cone Beam Computed Tomography.
    Br J Radiol. 2018 Nov 15:20180383. doi: 10.1259/bjr.20180383.
    PubMed     Abstract available


  36. TAU N, Berlin A, Yeung I, Halankar J, et al
    Quantitative assessment of dynamic (18)F-Fluoromethycholine PET and Dynamic Contrast Enhanced MRI in High Risk Prostate Cancer.
    Br J Radiol. 2018 Nov 1:20180568. doi: 10.1259/bjr.20180568.
    PubMed     Abstract available


  37. TURNER JH
    Recent advances in theranostics and challenges for the future.
    Br J Radiol. 2018;91:20170893.
    PubMed     Abstract available


    October 2018
  38. JERECZEK-FOSSA BA, Rojas DP, Zerini D, Fodor C, et al
    Re-irradiation for isolated local recurrence of prostate cancer: MONO-INSTITUTIONAL series of 64 patients treated with salvage stereotactic body radiotherapy (SBRT).
    Br J Radiol. 2018 Oct 31:20180494. doi: 10.1259/bjr.20180494.
    PubMed     Abstract available


    September 2018
  39. HEDGIRE S, Kilcoyne A, Tonyushkin A, Mao Y, et al
    Effect of androgen deprivation and radiation therapy on MRI fiber tractography in prostate cancer: Can we assess treatment response on imaging?
    Br J Radiol. 2018 Sep 13:20170170. doi: 10.1259/bjr.20170170.
    PubMed     Abstract available


    July 2018
  40. AZADI J, Nguyen ML, Leroy A, Macura KJ, et al
    The emerging role of imaging in prostate cancer secondary screening: multiparametric magnetic resonance imaging and the incipient incorporation of molecular imaging.
    Br J Radiol. 2018 Jul 26:20170960. doi: 10.1259/bjr.20170960.
    PubMed     Abstract available


    June 2018
  41. MULLANEY L, O'Shea E, Dunne MT, Thirion PG, et al
    A comparison of bladder volumes based on treatment planning Computed Tomography and BladderScan(R) BVI 6100 ultrasound device in a prostate radiation therapy population.
    Br J Radiol. 2018 Jun 11:20180160. doi: 10.1259/bjr.20180160.
    PubMed     Abstract available


  42. NGUYEN TB, Ushinsky A, Yang A, Nguyentat M, et al
    Utility of quantitative apparent diffusion coefficient measurements and normalized apparent diffusion coefficient ratios in the diagnosis of clinically significant peripheral zone prostate cancer.
    Br J Radiol. 2018 Jun 5:20180091. doi: 10.1259/bjr.20180091.
    PubMed     Abstract available


  43. MARTIN JM, Supiot S, Keall PJ, Catton CN, et al
    Moderately hypofractionated prostate external-beam radiotherapy: an emerging standard.
    Br J Radiol. 2018;91:20170807.
    PubMed     Abstract available


    May 2018
  44. KULKARNI HR, Singh A, Langbein T, Schuchardt C, et al
    Theranostics of prostate cancer: from molecular imaging to precision molecular radiotherapy targeting the prostate specific membrane antigen.
    Br J Radiol. 2018 May 15:20180308. doi: 10.1259/bjr.20180308.
    PubMed     Abstract available


  45. TIMON G, Ciardo D, Bazani A, Marvaso G, et al
    Short-term high precision radiotherapy for early prostate cancer with concomitant boost to the dominant lesion: ad interim analysis and preliminary results of phase II trial AIRC-IG-13218.
    Br J Radiol. 2018 May 11:20160725. doi: 10.1259/bjr.20160725.
    PubMed     Abstract available


    April 2018
  46. JADVAR H, Colletti PM
    (18)F-NaF/(223)RaCl2 theranostics in metastatic prostate cancer: treatment response assessment and prediction of outcome.
    Br J Radiol. 2018 Apr 9:20170948. doi: 10.1259/bjr.20170948.
    PubMed     Abstract available


    March 2018
  47. JUNG SI, Jeon HJ, Park HS, Yu MH, et al
    Multiparametric MR imaging of peripheral zone prostate cancer: effect of postbiopsy hemorrhage on cancer detection according to Gleason score and tumour volume.
    Br J Radiol. 2018 Mar 9:20180001. doi: 10.1259/bjr.20180001.
    PubMed     Abstract available


    February 2018
  48. GODDARD L, Brodin NP, Bodner WR, Garg M, et al
    Comparing photon and proton based hypofractioned sbrt for prostate cancer accounting for robustness and realistic treatment deliverability.
    Br J Radiol. 2018 Feb 13:20180010. doi: 10.1259/bjr.20180010.
    PubMed     Abstract available


  49. KING RB, Osman SO, Fairmichael C, Irvine DM, et al
    Efficacy of a rectal spacer with prostate SABR-first UK experience.
    Br J Radiol. 2018;91:20170672.
    PubMed     Abstract available


  50. DI PAOLA V, Cybulski A, Belluardo S, Cavicchioli F, et al
    Evaluation of periprostatic neurovascular fibers before and after radical prostatectomy by means of 1.5 t mri diffusion tensor imaging.
    Br J Radiol. 2018 Feb 1:20170318. doi: 10.1259/bjr.20170318.
    PubMed     Abstract available


    January 2018

  51. Addendum to Hricak H. MR imaging and MR spectroscopic imaging in the pre-treatment evaluation of prostate cancer. Br J Radiol 2005; 78: S103-S111.
    Br J Radiol. 2018 Jan 31:bjr11253478a. doi: 10.1259/bjr.11253478.
    PubMed    


  52. DUFFTON A, Sadozye A, Devlin L, MacLeod N, et al
    Safety and feasibility of prostate stereotactic ablative radiotherapy using multi-modality imaging and flattening filter free.
    Br J Radiol. 2018 Jan 17:20170625. doi: 10.1259/bjr.20170625.
    PubMed     Abstract available


  53. ELFATAIRY KK, Filson CP, Sanda MG, Osunkoya AO, et al
    In-bore MRI-guided biopsy: can it optimize the need for periodic biopsies in prostate cancer patients undergoing active surveillance? a pilot test-retest reliability study.
    Br J Radiol. 2018 Jan 8:20170603. doi: 10.1259/bjr.20170603.
    PubMed     Abstract available


  54. TEOH EJ, McGowan DR, Schuster DM, Tsakok M, et al
    Bayesian penalised likelihood reconstruction (Q.Clear) of (18)F-fluciclovine PET for imaging of recurrent prostate cancer: semi-quantitative and clinical evaluation.
    Br J Radiol. 2018 Jan 5:20170727. doi: 10.1259/bjr.20170727.
    PubMed     Abstract available


  55. DENIS-BACELAR AM, Chittenden SJ, McCready VR, Divoli A, et al
    Bone lesion absorbed dose profiles in patients with metastatic prostate cancer treated with molecular radiotherapy.
    Br J Radiol. 2018 Jan 2:20170795. doi: 10.1259/bjr.20170795.
    PubMed     Abstract available


    December 2017
  56. BOUSTANI AM, Pucar D, Saperstein L
    Molecular imaging of prostate cancer.
    Br J Radiol. 2017 Dec 15:20170736. doi: 10.1259/bjr.20170736.
    PubMed     Abstract available


    November 2017
  57. BRIZMOHUN APPAYYA M, Sidhu HS, Dikaios N, Johnston EW, et al
    Characterizing indeterminate (Likert-scored 3/5) peripheral zone prostate lesions with PSA density, PI-RADS scoring and qualitative descriptors on multi-parametric MRI.
    Br J Radiol. 2017 Nov 30:20170645. doi: 10.1259/bjr.20170645.
    PubMed     Abstract available


  58. TOMITA N, Soga N, Ogura Y, Furusawa J, et al
    Effects of dose-escalated radiotherapy in combination with long-term androgen deprivation on prostate cancer.
    Br J Radiol. 2017 Nov 22:20170431. doi: 10.1259/bjr.20170431.
    PubMed     Abstract available


  59. TANAKA O, Komeda H, Tamaki M, Seike K, et al
    Comparison of MRI visualisation between linearly placed iron-containing and non-iron-containing fiducial markers for prostate radiotherapy.
    Br J Radiol. 2017 Nov 9:20170612. doi: 10.1259/bjr.20170612.
    PubMed     Abstract available


  60. PIZARRO F, Hernandez A
    Optimization of radiotherapy fractionation schedules based on radiobiological functions.
    Br J Radiol. 2017;90:20170400.
    PubMed     Abstract available


  61. CIARDO D, Jereczek-Fossa BA, Petralia G, Timon G, et al
    Multimodal image registration for the identification of dominant intraprostatic lesion in high-precision radiotherapy treatments.
    Br J Radiol. 2017;90:20170021.
    PubMed     Abstract available


    August 2017
  62. KWON MR, Kim CK, Kim JH
    PI-RADS version 2: Evaluation of diffusion-weighted imaging interpretation between B = 1000 and B = 1500 s/mm2.
    Br J Radiol. 2017 Aug 22:20170438. doi: 10.1259/bjr.20170438.
    PubMed     Abstract available


    July 2017
  63. SAMLALI H, Udrescu C, Lapierre A, Enachescu C, et al
    Prospective evaluation of a specific technique of sexual function preservation in external beam radiotherapy for prostate cancer.
    Br J Radiol. 2017 Jul 27:20160877. doi: 10.1259/bjr.20160877.
    PubMed     Abstract available


  64. HAUTH E, Halbritter D, Jaeger H, Hohmuth H, et al
    Diagnostic value of semiquantitative and quantitative analysis of functional parameters in multiparametric MRI of the prostate.
    Br J Radiol. 2017 Jul 27:20170067. doi: 10.1259/bjr.20170067.
    PubMed     Abstract available


  65. GERLACH S, Kuhlemann I, Ernst F, Furweger C, et al
    Impact of robotic ultrasound image guidance on plan quality in SBRT of the prostate.
    Br J Radiol. 2017 Jul 27:20160926. doi: 10.1259/bjr.20160926.
    PubMed     Abstract available


    June 2017
  66. FLUX GD
    Imaging and dosimetry for radium-223: the potential for personalized treatment.
    Br J Radiol. 2017 Jun 27:20160748. doi: 10.1259/bjr.20160748.
    PubMed     Abstract available


    May 2017
  67. GASNIER A, Parvizi N
    Updates on the diagnosis and treatment of prostate cancer.
    Br J Radiol. 2017 May 30:20170180. doi: 10.1259/bjr.20170180.
    PubMed     Abstract available


  68. ROBINSON JL, Tzou KS, Parker AS, Heckman MG, et al
    GATA2 expression and biochemical recurrence following salvage radiation therapy for relapsing prostate cancer.
    Br J Radiol. 2017 May 9:20170174. doi: 10.1259/bjr.20170174.
    PubMed     Abstract available


    January 2017
  69. HARVEY H, Orton MR, Morgan VA, Parker C, et al
    Volumetry of the Dominant Intraprostatic Tumour Lesion: Intersequence and Interobserver Differences on Multiparametric MRI.
    Br J Radiol. 2017 Jan 5:20160416. doi: 10.1259/bjr.20160416.
    PubMed     Abstract available


    December 2016
  70. CHAN J, Carver A, Brunt JN, Vinjamuri S, et al
    Effect of androgen deprivation therapy on intra-prostatic tumour volume identified on 18F choline PET/CT for prostate dose painting radiotherapy.
    Br J Radiol. 2016 Dec 20:20160818.
    PubMed     Abstract available


    November 2016
  71. LJUNGBERG M, Pretorius PH
    SPECT/CT: an update on technological developments and clinical applications.
    Br J Radiol. 2016 Nov 15:20160402.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: